Sent: October 30, 2013
Subject: YA TSIE-In the Field
Hi, This is to confirm that the YA TSIE Study—The Botswana Combination Prevention Project (BCPP) is underway and the team deployed today 30th October in the field at both Ranaka and Digawana. While there have been challenges and some initial delay in study initiation, it is with great confidence in the team and their ability to rise up to challenges that I am confident this shall become one of BHP’s blue chip studies. I wish the team success and God’s Speed as they roll out this immensely challenging study. Joe Dr. Joseph Makhema C.E.O. Botswana Harvard AIDS Institute
It was the first week of June in 2015. The BCPP leadership team was stressed. There were even more conference calls than usual. Two upcoming events could change the course of the trial. The first was a June 11th meeting of the Data Safety Monitoring Board (DSMB) at the National Institutes of Health (NIH) in Bethesda. The second was the July meeting of the International AIDS Society (IAS) in Vancouver.
Loading file cabinets onto a truck in Lobatse, Botswana wasn’t in Morgan Packers’ job description. Neither was pressing contractors to bring renovations up to code at the Nyangabgwe Hospital Clinic, but unhesitatingly, she did both.
“She’s someone you trust to do a job well and on time,” said Dr. Shahin Lockman, one of Morgan’s mentors. “She’s resourceful, adaptable, and has the ability to work with new people in a completely new environment,” said Dr. Kenneth Maswabi, a colleague in Botswana. “Doing whatever needs to get done, that’s the nature of project management,” said Morgan herself. Continue reading →
With no cure or vaccine in sight, HIV/AIDS remains a devastating epidemic, particularly in sub-Saharan Africa where nearly 70% of new HIV infections occur. To curb HIV/AIDS, researchers have proposed a strategy to use drug treatment to decrease new transmissions so much that the epidemic eventually dies out. The concept requires changes in standards of when anti-retroviral therapy begins and who receives it. Could “treatment as prevention” prove to be the strategy to finally end the AIDS epidemic?
Imagine that you’re a young woman in southern Africa, giving birth to the child you’ve carried for nine months. Between the pain and the pushing, you feel both excitement and dread. At the antenatal clinic several months ago, you learned that you were infected with HIV. The doctor gave you antiretroviral (ARV) drugs to prevent your child from being born with HIV. You pray that they worked.
There are not many couples in which both husband and wife are first authors on a paper in the prestigious New England Journal of Medicine, but Drs.Roger Shapiro and Shahin Lockman are one of them. In addition to being researchers for the Harvard AIDS Initiative, both are also physicians specializing in infectious diseases. Together they have three sons, ages three, six and nine. And in spite of constant demands on their schedules, Shapiro and Lockman spend a significant amount of time mentoring young HIV/AIDS researchers.